These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38910324)

  • 1. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
    Basnet S; Van der Heijden M; Quixabeira DCA; Jirovec E; Grönberg-Vähä-Koskela SAM; Clubb JHA; Kanerva A; Pakola S; Haybout L; Arias V; Hemminki O; Kudling T; Zafar S; Cervera-Carrascon V; Santos JM; Hemminki A
    Mol Ther; 2024 Sep; 32(9):3114-3127. PubMed ID: 38910324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oncolytic adenovirus co-expressing a bi-specific T cell engager and IL-2 for the treatment of ovarian cancer.
    Ayele K; Wakimoto H; Saha D
    Mol Ther; 2024 Sep; 32(9):2810-2813. PubMed ID: 39178849
    [No Abstract]   [Full Text] [Related]  

  • 3. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.
    Peters PN; Whitaker RS; Lim F; Russell S; Bloom EA; Pollara J; Strickland KC; Cantwell MJ; Beg A; Berchuck A; Antonia S; Previs RA
    Neoplasia; 2024 Nov; 57():101056. PubMed ID: 39276533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.
    Basnet S; Santos JM; Quixabeira DCA; Clubb JHA; Grönberg-Vähä-Koskela SAM; Arias V; Pakola S; Kudling TV; Heiniö C; Havunen R; Cervera-Carrascon V; Sorsa S; Anttila M; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2023 Mar; 28():59-73. PubMed ID: 36699617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
    Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
    Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
    Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
    Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
    Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
    Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
    Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
    Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
    Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
    Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
    Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
    Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
    Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
    Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
    Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
    Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
    Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.
    Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R
    Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.